Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

Cooper Flagg #2 of the Duke Blue Devils defends Jason Asemota #5 of the Baylor Bears during the second round of the 2025 NCAA ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 20 ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Eli Lilly stock has advanced more than 200% over ... makes it a fantastic buy today. Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Amgen, Novo Nordisk ...

(Reuters) -Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday at the ...

FDA acted within its discretion in declaring end to shortage Compounders must stop making their versions of Zepbound Drug compounders making copycat versions of Eli Lilly & Co. ’s weight loss drug ...

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

In its fourth quarter 2024 investor letter, RiverPark Large Growth Fund emphasized stocks such as Eli Lilly and Company (NYSE ... current GLP-1 drugs, though no longer supply constrained, are ...